Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1993 1
2002 3
2005 2
2007 1
2008 3
2010 1
2011 1
2012 1
2016 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Ito T, Lee L, Jensen RT. Ito T, et al. Expert Opin Pharmacother. 2016 Nov;17(16):2191-2205. doi: 10.1080/14656566.2016.1236916. Epub 2016 Sep 23. Expert Opin Pharmacother. 2016. PMID: 27635672 Free PMC article. Review.
All advances that controlled hormone-excess-states or facilitated-control were covered. These include new medical-therapies [serotonin-synthesis inhibitors(telotristat), Pasireotide, new agents for treating ACTHomas], increased dosing with conventional therapies (oc …
All advances that controlled hormone-excess-states or facilitated-control were covered. These include new medical-therapies [serotoni …
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.
Jensen RT, Berna MJ, Bingham DB, Norton JA. Jensen RT, et al. Cancer. 2008 Oct 1;113(7 Suppl):1807-43. doi: 10.1002/cncr.23648. Cancer. 2008. PMID: 18798544 Free PMC article. Review.
Pancreatic endocrine tumors (PETs) can occur as part of 4 inherited disorders, including Multiple Endocrine Neoplasia type 1 (MEN1), von Hippel-Lindau disease (VHL), neurofibromatosis 1 (NF-1) (von Recklinghausen disease), and the tuberous sclerosis complex ( …
Pancreatic endocrine tumors (PETs) can occur as part of 4 inherited disorders, including Multiple Endocrine Neoplasia t …
Current surgical management of pancreatic endocrine tumor liver metastases.
Pavlidis TE, Psarras K, Symeonidis NG, Pavlidis ET, Sakantamis AK. Pavlidis TE, et al. Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):243-7. doi: 10.1016/s1499-3872(11)60040-4. Hepatobiliary Pancreat Dis Int. 2011. PMID: 21669565 Review.
BACKGROUND: The management of metastatic disease in pancreatic endocrine tumors (PETs) demands a multidisciplinary approach and the cooperation of several medical specialties. ...Palliative excisions include aggressive tumor debulking surgeries in well-differ …
BACKGROUND: The management of metastatic disease in pancreatic endocrine tumors (PETs) demands a multidisciplinary approach an …
p21 Protein Outperforms Clinico-pathological Criteria in Predicting Liver Metastases in Pancreatic Endocrine Tumors.
Nasir A, Ahmed MK, Saller JJ, Henderson-Jackson EB, Malafa MP, Yeatman TJ, Coppola D. Nasir A, et al. Cancer Genomics Proteomics. 2023 Nov-Dec;20(6):522-530. doi: 10.21873/cgp.20402. Cancer Genomics Proteomics. 2023. PMID: 37889062 Free PMC article.
BACKGROUND/AIM: P21 is a cyclin-dependent kinase inhibitor regulating the cell cycle as a tumor suppressor. Using a p21 immunohistochemistry (IHC) assay, we compared tumor p21 levels with conventional clinico-pathological criteria in primary pancreatic end …
BACKGROUND/AIM: P21 is a cyclin-dependent kinase inhibitor regulating the cell cycle as a tumor suppressor. Using a p21 immunohistoch …
Pathological differential diagnosis of solid-pseudopapillary neoplasm and endocrine tumors of the pancreas.
Liu BA, Li ZM, Su ZS, She XL. Liu BA, et al. World J Gastroenterol. 2010 Feb 28;16(8):1025-30. doi: 10.3748/wjg.v16.i8.1025. World J Gastroenterol. 2010. PMID: 20180245 Free PMC article.
AIM: To investigate differential points of solid-pseudopapillary neoplasm (SPN) of the pancreas and pancreatic endocrine tumor (PET). METHODS: Ten cases of SPN and fourteen cases of PET were studied in this retrospective study. ...The mean size of the tumors …
AIM: To investigate differential points of solid-pseudopapillary neoplasm (SPN) of the pancreas and pancreatic endocrine tu …
WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.
Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H, Heitz PU, Kloeppel G, Komminoth P, Perren A. Schmitt AM, et al. Am J Surg Pathol. 2007 Nov;31(11):1677-82. doi: 10.1097/PAS.0b013e31805f675d. Am J Surg Pathol. 2007. PMID: 18059224
BACKGROUND: It is difficult to predict the biologic behavior of pancreatic endocrine tumors in absence of metastases or invasion into adjacent organs. ...CONCLUSIONS: The 2004 WHO classification with 4 risk groups is very reliable for predicting both disease-free su …
BACKGROUND: It is difficult to predict the biologic behavior of pancreatic endocrine tumors in absence of metastases or invasi …
Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome.
Gibril F, Jensen RT. Gibril F, et al. Curr Gastroenterol Rep. 2005 May;7(2):114-21. doi: 10.1007/s11894-005-0049-2. Curr Gastroenterol Rep. 2005. PMID: 15802099 Review.
Gastrinomas producing Zollinger-Ellison syndrome are the most frequent symptomatic, malignant pancreatic endocrine tumor syndrome. Recently, a number of important studies have examined their molecular pathogenesis and natural history and provided important gu …
Gastrinomas producing Zollinger-Ellison syndrome are the most frequent symptomatic, malignant pancreatic endocrine tumor …
Genotype-phenotype analysis in multiple endocrine neoplasia type 1.
Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ, Evans DB. Kouvaraki MA, et al. Arch Surg. 2002 Jun;137(6):641-7. doi: 10.1001/archsurg.137.6.641. Arch Surg. 2002. PMID: 12049533
The phenotypic expression of MEN 1 in affected individuals included hyperparathyroidism in 74%, pancreatic endocrine tumors in 51%, and pituitary tumors in 35%. Twelve of 14 insulinomas occurred in patients with pituitary tumors. ...Mutations were most common in exo …
The phenotypic expression of MEN 1 in affected individuals included hyperparathyroidism in 74%, pancreatic endocrine tumors in …
VIPomas: an update in diagnosis and management in a series of 11 patients.
Nikou GC, Toubanakis C, Nikolaou P, Giannatou E, Safioleas M, Mallas E, Polyzos A. Nikou GC, et al. Hepatogastroenterology. 2005 Jul-Aug;52(64):1259-65. Hepatogastroenterology. 2005. PMID: 16001675
BACKGROUND/AIMS: VIPoma is a rare pancreatic endocrine tumor (PET) which secretes excessive amounts of VIP (Vasoactive Intestinal Peptide) that causes a special clinical syndrome characterized by secretory diarrhea, hypokalemia and achlorhydria. Among a total …
BACKGROUND/AIMS: VIPoma is a rare pancreatic endocrine tumor (PET) which secretes excessive amounts of VIP (Vasoactive …
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R; Barcelona Consensus Conference participants. Jensen RT, et al. Neuroendocrinology. 2012;95(2):98-119. doi: 10.1159/000335591. Epub 2012 Feb 15. Neuroendocrinology. 2012. PMID: 22261919 Free PMC article. No abstract available.
16 results